Zolgensma (onasemnogene abeparvovec): risk for thrombotic microangiopathy
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
| Medicine name |
Zolgensma
|
| Active substance |
Onasemnogene abeparvovec
|
| Procedure number |
EMEA/H/C/004750/II/0008
|
| Regulatory outcome |
Variation
|
| DHPC type |
Type II variation
|
| Human ATC code |
M09AX09
|
| Dissemination date |
18/03/2021
|